Skip to main content
SearchLoginLogin or Signup

Reviews of "Use of Indomethacin for mild and moderate Covid -19 patients. A Randomized Control Trial"

Vikas Sukhatme (Emory University) | 📗📗📗📗◻️ • Colin Brown (Edinburgh Napier University) | 📗📗📗📗◻️

Published onFeb 01, 2022
Reviews of "Use of Indomethacin for mild and moderate Covid -19 patients. A Randomized Control Trial"
key-enterThis Pub is a Review of
Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial

ABSTRACTIntroductionIndomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients.Materials & MethodsA total of 210 RT-PCR-positive COVID-19 patients, who provided consent were allotted, to control or case arm, based on block randomisation. The control arm received standard of care comprising paracetamol, ivermectin, and other adjuvant therapies. The patients in the case arm received indomethacin instead of paracetamol, with other medications retained. The primary endpoint was the development of hypoxia/desaturation with SpO2 ≤ 93, while time to become afebrile and time for cough and myalgia resolution were the secondary endpoints.ResultsThe results of 210 patients were available, with 103 and 107 patients in the indomethacin and paracetamol arms, respectively. We monitored patient profiles along with everyday clinical parameters. Blood chemistry at the time of admission and discharge was assessed.As no one in either of the arms required high-flow oxygen, desaturation with SpO2 level of 93 and below was an important goal. In the indomethacin group, none of the 103 patients developed desaturation. On the other hand, 20 of the 107 patients in the paracetamol arm developed desaturation. Patients who received indomethacin also experienced more rapid symptomatic relief than those in the paracetamol arm, with most symptoms disappearing in half the time. 56 patients out of 107 in the paracetamol arm had fever on the seventh day, while no patient in the indomethacin group had fever. Neither arm reported any adverse event. The fourteenth-day follow-up revealed that the paracetamol arm patients had faced several discomforts, including myalgia, joint pain, and tiredness; indomethacin arm patients mostly complained only of tiredness.ConclusionIndomethacin is a safe and effective drug for treating patients with mild and moderate covid-19.

To read the original manuscript, click the link above.

Summary of Reviews: This preprint evaluates the clinical efficacy of indomethacin for mild and moderate COVID-19, and finds that patients treated with indomethacin experienced oxygen desaturation less frequently with more rapid recovery times. Reviewers deemed the results compelling and reliable.

Reviewer 1 (Vikas Sukhatme) | 📗📗📗📗◻️

Reviewer 2 (Colin Brown) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.

No comments here
Why not start the discussion?